Literature DB >> 2580598

Serotonin release in human cerebral cortex and its modulation via serotonin receptors.

E Schlicker, F Brandt, K Classen, M Göthert.   

Abstract

Human cerebral cortex slices were prepared from brain tissue which had to be removed in order to gain access to deep-seated tumours. Subsequent to incubation with [3H]serotonin, the slices were superfused with physiological salt solution containing paroxetine, and 3H overflow was evoked by electrical field stimulation. The evoked tritium overflow (86% of which was accounted for by unmetabolized [3H]serotonin) was abolished by tetrodotoxin or omission of calcium from the superfusion fluid. Unlabelled serotonin decreased, and the serotonin receptor antagonist metitepin increased, the evoked overflow. The inhibition produced by serotonin was antagonized by metitepin. It is concluded that serotonin release in human cerebral cortex is modulated by inhibitory serotonin receptors, which may be localized presynaptically on the serotoninergic nerve fibers themselves. There are marked similarities between human and rat brain cortex with respect to action potential-induced, Ca2+-dependent serotonin release and its modulation via serotonin receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2580598     DOI: 10.1016/0006-8993(85)91559-8

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

1.  Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex.

Authors:  Benjamin Berger; Anna Katharina Rothmaier; Franziska Wedekind; Josef Zentner; Thomas J Feuerstein; Rolf Jackisch
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

2.  Proceedings of the British Pharmacological Society. 6th-8th January, 1988. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

3.  Postmortem- and cryostability of the potassium-evoked release of [3H]5-hydroxytryptamine from rat cerebral cortical miniprisms.

Authors:  C J Fowler; G Thorell; I Fagervall
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

4.  Presynaptic inhibitory serotonin autoreceptors in the human hippocampus.

Authors:  E Schlicker; K Fink; J Zentner; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996 Aug-Sep       Impact factor: 3.000

5.  The pharmacological properties of the presynaptic serotonin autoreceptor in the pig brain cortex conform to the 5-HT1D receptor subtype.

Authors:  E Schlicker; K Fink; M Göthert; D Hoyer; G Molderings; I Roschke; P Schoeffter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

6.  Pharmacological diversity between native human 5-HT1B and 5-HT1D receptors sited on different neurons and involved in different functions.

Authors:  M Marcoli; G Maura; C Munari; A Ruelle; M Raiteri
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

7.  Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats.

Authors:  H Sershen; A Hashim; A Lajtha
Journal:  Neurochem Res       Date:  1994-11       Impact factor: 3.996

8.  Modulation of 5-hydroxytryptamine release by presynaptic inhibitory alpha 2-adrenoceptors in the human cerebral cortex.

Authors:  M Raiteri; G Maura; S Folghera; P Cavazzani; G C Andrioli; E Schlicker; R Schalnus; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-11       Impact factor: 3.000

9.  The 5-hydroxytryptamine 5-HT1D receptor subtype is negatively coupled to adenylate cyclase in calf substantia nigra.

Authors:  P Schoeffter; C Waeber; J M Palacios; D Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-06       Impact factor: 3.000

10.  Subclassification of presynaptic 5-HT autoreceptors in the human cerebral cortex as 5-HT1D receptors.

Authors:  K Fink; J Zentner; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-10       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.